Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía

dc.contributor.author	López Ramos, Hugo Enrique
dc.contributor.author	Medina Rico, Mauricio Alejandro
dc.contributor.author	Bastidas Rosas, Danielle
dc.contributor.author	Lara B.
dc.date.accessioned	2022-05-31T17:11:30Z
dc.date.accessioned	2023-05-11T19:37:30Z
dc.date.available	2022-05-31T17:11:30Z
dc.date.available	2023-05-11T19:37:30Z
dc.date.created	2018
dc.identifier	https://revistamexicanadeurologia.org.mx/index.php/rmu/article/view/96	spa
dc.identifier.issn	0035-0001	spa
dc.identifier.uri	https://hdl.handle.net/20.500.12032/117269
dc.description.abstract	Benign prostatic hyperplasia affects 50% of the population and is more frequent in the seventh and eighth decades of life. There are currently different treatments for benign prostatic hyperplasia and pharmacologic management is considered first-line trea	spa
dc.format	PDF	spa
dc.format.mimetype	application/pdf	spa
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject	Alfuzosin	spa
dc.subject	Doxazosin	spa
dc.subject	Dutasteride	spa
dc.subject	Fesoterodine	spa
dc.subject	Finasteride	spa
dc.subject	Naftopidil	spa
dc.subject	Sabal Extract	spa
dc.subject	Sildenafil	spa
dc.subject	Silodosin	spa
dc.subject	Tadalafil	spa
dc.subject	Tamsulosin	spa
dc.subject	Article	spa
dc.subject	Clinical Effectiveness	spa
dc.subject	Drug Efficacy	spa
dc.subject	Human	spa
dc.subject	Palliative Therapy	spa
dc.subject	Patient Preference	spa
dc.subject	Phytotherapy	spa
dc.subject	Practice Gu	spa
dc.title	Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía

Files in this item

Files	Size	Format	View
a4174.pdf	394.7Kb	application/pdf	View/Open

Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/